Survival and Clinical Progression in Barth Syndrome: Insights From the Barth Syndrome Foundation's Database of 502 Affected Individuals
Open Access
- 3 May 2026
- journal article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (3) , e70189
Abstract
Barth syndrome (BTHS; OMIM 302060) is an ultra‐rare, life‐limiting genetic disorder characterized by cardiomyopathy, skeletal muscle myopathy, neutropenia, gastrointestinal issues, and fatigue. Formal analyses of survival and clinical progression remain limited. Barth Syndrome Foundation has maintained an intake database ( n = 502), representing > 80% of the known global population, as well as a patient‐inputted registry for a subset of individuals ( n = 162) with up to 11 years of longitudinal outcome data. We estimate the survival curve, identify factors associated with mortality, characterize clinical manifestations over time, and evaluate causes of death. Death disproportionately affected young children, with a 59% transplant‐free survival rate for those age < 5. The risk of death plateaued between ages 5–25 before rising again. Heart transplantation (HR = 0.316, 95% CI: 0.162–0.619, p < 0.001) and living in a developed country (HR = 0.109, 95% CI: 0.018–0.659, p < 0.05) were associated with reduced risk of death. Clinical manifestations increased with age, with musculoskeletal/fatigue (66%) being most frequent. Top causes of death were cardiac‐related complications, with cardiomyopathy/heart failure (51.3%), mostly in young children < 5, and arrhythmia/cardiac arrest (15%). This is the most comprehensive longitudinal assessment of BTHS survival, mortality risk, and clinical manifestation progression. Early childhood is a period of high mortality risk, driven in large part by heart failure. Although risk of death and hospitalizations plateaued between ages 5–25, the clinical burden of BTHS increases throughout the lifespan. Our results may guide clinical care, identify time windows for optimal intervention, and help clinicians better recognize BTHS clinical features.Keywords
Funding Information
- Barth Syndrome Foundation (#22‐3755704)
- Silicon Valley Community Foundation
This publication has 32 references indexed in Scilit:
- Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular ImagingEuropean Heart Journal - Cardiovascular Imaging, 2015
- Barth syndromeOrphanet Journal of Rare Diseases, 2013
- Natural history of Barth syndrome: a national cohort study of 22 patientsOrphanet Journal of Rare Diseases, 2013
- Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotypeNeurology, 2011
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005
- Modeling Late Entry Bias in Survival AnalysisBiometrics, 2005
- A novel X-linked gene, G4.5. is responsible for Barth syndromeNature Genetics, 1996
- GeneReviews®1993
- An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytesJournal of the Neurological Sciences, 1983
- An X-Linked Recessive Cardiomyopathy with Abnormal MitochondriaPediatrics, 1979